⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
WVE News
Wave Life Sciences Ltd. Ordinary Shares
Form 8-K
sec.gov
WVE
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
WVE
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
globenewswire.com
WVE
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
globenewswire.com
WVE
ALNY
DNLI
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
globenewswire.com
WVE
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
globenewswire.com
WVE
Exploring Investment Opportunities in the Expanding RNA Therapy Clinical Trials Market: A USD 4.28 Billion Valuation by 2031
globenewswire.com
MRNA
BNTX
WVE
Ambulatory EHR Excellence 2026: Top Vendors Recognized for Breakthrough Innovation and Specialty User Satisfaction in Black Book 2026 Surveys
accessnewswire.com
NTST
ATHA
QRHC
PROV
WVE
MTC
WELL
MED
ORCL
SPRY
PATN
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
globenewswire.com
WVE
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
WVE